Jasper Therapeutics Inc (JSPR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.51+6.48%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · JSPR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
JSPR — capital allocation — Material Modification to Rights of Security Holders
Dated 2026-11-04
Material Modification to Rights of Security Holders. To the extent required by
Why it matters: Starting the FSGS cohort would show Jasper is extending KP-104 into another kidney disease. A delay would slow that plan.
Supportive ifJasper reports that the first FSGS patient received a dose by March 31, 2027.
Worry ifJasper reports no first FSGS patient dose by March 31, 2027, or says the cohort start is delayed.
Why it matters: A meeting with the FDA is a key step toward a possible BLA. Jasper has not yet shared the next steps.
Supportive ifJasper reports a pre-BLA meeting with the FDA or gives clear next steps by March 31, 2027.
Worry ifJasper reports that the meeting or next steps have slipped past March 31, 2027.
Why it matters: Management tied its plan to a runway through the second half of 2028. Updated cash figures can show whether that plan still holds.
Worry ifJasper confirms planned operations remain funded through the second half of 2028. It discloses no need for new financing.
Less concerning ifJasper shortens its stated runway to before the second half of 2028. Or it discloses a need for new financing sooner.
Why it matters: A CTA or IND filing would move KP-701 toward its first human study. A missed filing would push back the program.
Supportive ifJasper files a CTA or IND for KP-701 by March 31, 2027.
Worry ifJasper has not filed a CTA or IND by March 31, 2027, or reports a delay.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$339 on $10,000 · ±3.4% | How much price usually moves either way. |
| Bad day | $969 loss on $10,000 · 9.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,337 loss on $10,000 · 83.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The offer can cut future share dilution, but paying for tendered warrants uses cash. The final count shows the trade-off.
Watch forJasper reports that a large share of the 12.35 million warrants were tendered and canceled, with the cash paid disclosed.
Also watch forFew warrants are tendered, leaving most of the 12.35 million warrants outstanding. Or Jasper reports a material cash cost from the offer.